SCHEMBL723977

SCHEMBL723977

COc1ccc(C(=O)NCCN)cc1-c1ccnc2cc(-c3cc(OC)c(OC)c(OC)c3)oc12

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.42
FYN P06241 1/20 0.42
PTK2 Q05397 1/20 0.39
KMT2A Q03164 4/20 0.39
TERT O14746 2/20 0.39
MEN1 O00255 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK14 Q16539 1/20 0.38
BRD4 O60885 2/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16429205 0.96 KMT2A (0.41) CFTRFYNKMT2AMEN1BRD4
SCHEMBL10267307 0.91 CFTR (0.46) CFTRFYNPTK2KMT2AMEN1
SCHEMBL723183 0.88 KMT2A (0.44) FYNKMT2AMEN1BRD4MAPT
SCHEMBL15210392 0.87 KMT2A (0.42) CFTRKMT2ATERTMEN1KDM4E
SCHEMBL15210569 0.86 NPC1 (0.43) CFTRFYNKMT2AMEN1BRD4
SCHEMBL723595 0.86 FYN (0.43) CFTRFYNKMT2AMEN1BRD4
SCHEMBL725317 0.86 FYN (0.45) FYNBRD4
SCHEMBL722941 0.86 CYP1A1 (0.40) FYNBRD4MAPT
SCHEMBL15210445 0.85 FYN (0.42) CFTRFYNKMT2AMEN1BRD4
SCHEMBL724404 0.85 KDM4C (0.42) FYNBRD4POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB CFTR 1666/4885FYN 33/4885PTK2 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.